DeCure for SSR4-congenital disorder of glycosylation
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for SSR4-congenital disorder of glycosylation — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSSR4-congenital disorder of glycosylation maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ssr4-congenital disorder of glycosylation is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In a 2014 study, three patients with variants in the X-linked SSR4 gene were identified among a cohort biochemically diagnosed with congenital disorders of glycosylation. Two of the variants resulted in absence of SSR4 expression, and in those cases, expression of other TRAP complex proteins was also reduced. Over-expression of the wild-type SSR4 allele partially restored glycosylation of a marker protein and expression of the other TRAP complex members in patient fibroblasts, providing the first evidence that the TRAP complex is directly involved in N-glycosylation. No clinical outcomes or therapeutic interventions were reported for these patients.
A 2021 review of treatment options for congenital disorders of glycosylation states that available therapies remain limited and are often constrained to symptomatic management of disease manifestations. It notes that recent years have seen novel therapies aimed at both the causative defect and secondary disease manifestations transferred from bench to bedside, but provides no specific data on SSR4-CDG or any drug efficacy. A 2006 case report on a patient with CDG type Ia, a different genetic subtype, described significant normalisation of hypoglycosylated transferrin over a 7-year follow-up, but the authors caution that isoelectric focusing has limits of detection and subtle changes can be overlooked, recommending re-testing with a different method when clinical suspicion is high.
No drug, compound, or intervention is named or tested in any of these abstracts for SSR4-CDG. The only experimental manipulation is genetic over-expression of the wild-type allele in fibroblasts, which is not a therapy. The evidence base for any pharmacological treatment of SSR4-CDG is therefore absent. What is missing is any clinical trial, any patient-derived data on drug response, any biomarker validation beyond transferrin isoelectric focusing, and any funding for a natural history study that could stratify patients by residual TRAP complex expression or glycosylation status.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Genetics · 2021 · 41 citations · open access
Treatment Options in Congenital Disorders of Glycosylation
AbstractDespite advances in the identification and diagnosis of congenital disorders of glycosylation (CDG), treatment options remain limited and are often constrained to symptomatic management of disease manifestations. However, recent years have seen significant advances in treatment and novel therapies aimed both at the causative defect and secondary disease manifestations have been transferred from bench to bedside. In this review, we aim to give a detailed overview of the available therapies and rising concepts to treat these ultra-rare diseases.
Journal of Inherited Metabolic Disease · 2006 · 20 citations
Stabilization of hypoglycosylation in a patient with congenital disorder of glycosylation type Ia
AbstractA follow-up over 7 years on a patient with congenital disorder of glycosylation type Ia showed a significant normalization of hypoglycosylated transferrin. Isoelectric focusing for serum transferrin is a widely used screening method but there could be a limit of detection and the subtle changes can be also overlooked. Re-test with a different method is desirable, especially when the clinical suspicion for congenital disorder of glycosylation is high.
Congenital disorder of glycosylation caused by a mutation in <i>SSR4</i> , the signal sequence receptor 4 protein of the TRAP complex (789.3)
AbstractCongenital Disorders of Glycosylation (CDG) are a family of genetic disorders affecting the glycosylation pathway or the trafficking of glycoproteins. Nearly 50 genes causing CDG have been described, but many patients biochemically diagnosed with CDG do not have mutations in known genes. Among our CDG patients, we identified by exome saequencing, in three patients, new variants of the X‐linked SSR4 gene which encodes a protein of the heterotetrameric translocon‐associated protein (TRAP) complex. Two of these variants results in the absence of SSR4 expression. In these cases, we observed that expression of other TRAP complex proteins was also reduced. The glycosylation marker Glyc‐ER‐GFP was used to confirm the underglycosylation in fibroblasts from patients. Over‐expression of the wild type SSR4 allele partially restores glycosylation of the marker and expression of the other members of the TRAP complex. This is the first evidence that the TRAP complex, which binds to the oligosaccharyltransferase complex, is directly involved in N‐glycosylation. Grant Funding Source : Supported by the National Institutes of Health grant [R01DK55615] and “The Rocket Fund”.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
